Age, years |
59 (48-65) |
56 (48-61) |
0.40 |
Male gender, n (%) |
26 (84) |
24 (62) |
0.04 |
BMI, kg/m2
|
31 (29-35) |
30 (25-34) |
0.20 |
Smoking Status, n (%) |
|
|
|
None
|
14 (45)
|
27 (69)
|
|
Active Smoker
|
0 (0)
|
2 (5)
|
|
Former Smoker
|
17 (55)
|
10 (26)
|
|
Smoking time, years |
30 (10-40) |
15 (13-25) |
0.25 |
Comorbidities, n (%) |
|
|
|
COPD
|
5 (16)
|
2 (5)
|
0.13
0.07
0.15
0.46
0.86
0.11
|
Hypertension
|
16 (52)
|
12 (31)
|
|
DM
|
13 (42)
|
10 (26)
|
|
CAD
|
3 (10)
|
2 (5)
|
|
CHF
|
1 (3)
|
1 (2)
|
|
Malignancy
|
0 (0)
|
3 (8)
|
|
Charlson Comorbidity Index |
1 (1-2) |
1 (1-2) |
0.16 |
Disease Severity |
|
|
|
1- No O2 Therapy
|
0 (0)
|
18 (46)
|
<0.001
|
2- Only O2 Therapy
|
3 (10)
|
21 (54)
|
|
3- NIV or HFNC
|
23 (74)
|
0 (0)
|
|
4- IMV
|
5 (16)
|
0 (0)
|
|
APACHE-2 Score |
11 (8-15) |
- |
|
Treatment, n (%) |
|
|
|
Hydroxychloroquine
|
21 (68)
|
33 (85)
|
0.09
<0.001
<0.001
<0.001
0.009
0.2
|
Favipravir
|
31 (100)
|
19 (49)
|
|
Corticosteroid
|
26 (83)
|
3 (8)
|
|
Convalescent plasma
|
12 (39)
|
0 (0)
|
|
Tocilizumab
|
5 (16)
|
0 (0)
|
|
Antibiotics
|
31 (100)
|
37 (95)
|
|
Complications, n (%) |
|
|
|
Acute renal failure
|
4 (13)
|
2 (5)
|
0.39
0.045
0.26
|
Hepatotoxicity
|
9 (29)
|
4 (10)
|
|
Sepsis
|
1 (3)
|
0 (0)
|
|
Length of hospital stay, days |
19 (14-28) |
8 (6-11) |
<0.001 |
Length of ICU stay, days |
9 (6-15) |
- |
|
Time from symptoms to follow up, days |
209 (189-219) |
190 (186-209) |
0.016 |